Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALM-PAH phase 3 trial of once-daily inhaled treprostinil palmitil in pulmonary arterial hypertension
MOH_2026-06-23_016897Phase 3Not yet recruiting
- Sponsor
- Insmed Incorporated
- Start
- Jun 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing TPIP with Placebo (2 arms). Primary endpoint: Change in 6-minute walk distance at Week 24. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2026-06-23_016897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-06-23_016897.